Harnessing neuroplasticity for clinical applications

Steven C. Cramer, Mriganka Sur, Bruce H. Dobkin, Charles O'Brien, Terence D. Sanger, John Q. Trojanowski, Judith M. Rumsey, Ramona Hicks, Judy Cameron, Daofen Chen, Wen G. Chen, Leonardo G. Cohen, Christopher Decharms, Charles J. Duffy, Guinevere F. Eden, Eberhard E. Fetz, Rosemarie Filart, Michelle Freund, Steven J. Grant, Suzanne HaberPeter W. Kalivas, Bryan Kolb, Arthur F. Kramer, Minda Lynch, Helen S. Mayberg, Patrick S. McQuillen, Ralph Nitkin, Alvaro Pascual-Leone, Patricia Reuter-Lorenz, Nicholas Schiff, Anu Sharma, Lana Shekim, Michael Stryker, Edith V. Sullivan, Sophia Vinogradov

Research output: Contribution to journalReview articlepeer-review

761 Scopus citations


Neuroplasticity can be defined as the ability of the nervous system to respond to intrinsic or extrinsic stimuli by reorganizing its structure, function and connections. Major advances in the understanding of neuroplasticity have to date yielded few established interventions. To advance the translation of neuroplasticity research towards clinical applications, the National Institutes of Health Blueprint for Neuroscience Research sponsored a workshop in 2009. Basic and clinical researchers in disciplines from central nervous system injury/stroke, mental/addictive disorders, paediatric/developmental disorders and neurodegeneration/ageing identified cardinal examples of neuroplasticity, underlying mechanisms, therapeutic implications and common denominators. Promising therapies that may enhance training-induced cognitive and motor learning, such as brain stimulation and neuropharmacological interventions, were identified, along with questions of how best to use this body of information to reduce human disability. Improved understanding of adaptive mechanisms at every level, from molecules to synapses, to networks, to behaviour, can be gained from iterative collaborations between basic and clinical researchers. Lessons can be gleaned from studying fields related to plasticity, such as development, critical periods, learning and response to disease. Improved means of assessing neuroplasticity in humans, including biomarkers for predicting and monitoring treatment response, are needed. Neuroplasticity occurs with many variations, in many forms, and in many contexts. However, common themes in plasticity that emerge across diverse central nervous system conditions include experience dependence, time sensitivity and the importance of motivation and attention. Integration of information across disciplines should enhance opportunities for the translation of neuroplasticity and circuit retraining research into effective clinical therapies.

Original languageEnglish (US)
Pages (from-to)1591-1609
Number of pages19
Issue number6
StatePublished - Jun 2011

Bibliographical note

Funding Information:
This work is based on a workshop sponsored by the National Institutes of Health Blueprint for Neuroscience Research and held in April, 2009. The views expressed herein do not necessarily represent the official views of the National Institutes of Health, the U.S. Department of Health and Human Services, or any other agency of the United States Government. Conflict of interest: Steven Cramer has received grant support from GlaxoSmithKline, Stem Cell Therapeutics and Panasonic and has received consulting income from GlaxoSmithKline, Stem Cell Therapeutics, Pfizer, Photothera, Allergan and Asubio. Christopher deCharms is an employee and stockholder in Omneuron, Inc., a research company that develops neuroimaging approaches for diagnosing and treating neurologic and psychiatric diseases. Helen S. Mayberg holds intellectual property in the field of deep brain stimulation for depression and is a consultant for St Jude Medical. Charles O’Brien has served as a consultant in the past year to Gilead, Alkermes, Reckitt and Embera. Alvaro Pascual-Leone serves on the medical advisory board for Nexstim, Neuronix, Neosync and Starlab.


  • clinical assessment
  • neuroplasticity
  • retraining
  • therapeutics


Dive into the research topics of 'Harnessing neuroplasticity for clinical applications'. Together they form a unique fingerprint.

Cite this